--Researchers Presented Positive Preclinical Data That Set the Stage for Longer-Term Tiara Studies Now Underway and Human Trials Planned for 2013--
--Researchers Also Presented Preliminary Registry Study Results Showing Improved Clinical Status in Refractory Angina Patients Implanted with Neovasc Reducer™--
TSX Venture Exchange: NVC
VANCOUVER, Oct. 23, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that its Tiara™ transcatheter mitral valve in preclinical development for the treatment of mitral valve disease was selected for an oral presentation as a "Best" New Device Concept for 2012 during an opening session at the 24 th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. Ten abstracts were selected for this honor from among 1750 abstracts submitted. A second oral presentation of Tiara data is scheduled for tomorrow. Researchers are also presenting Registry data showing that refractory angina patients implanted with the Neovasc Reducer™ have demonstrated improved clinical status and had no adverse events six months after implantation."This has been a very positive meeting for Neovasc as we continue to generate positive data that support the advancement of both the Tiara transcatheter mitral valve program and the Reducer, our device-based therapy for patients with refractory angina," noted Alexei Marko, CEO of Neovasc. "Early Registry data for the Reducer confirm that patients exhibit significant, measurable clinical benefits post-implantation, and the Tiara program is generating a great deal of interest as the successful completion of our acute preclinical testing has enabled us to begin long-term animal safety studies. If all goes well, we anticipate Tiara human trials will commence in 2013." The Tiara program is a novel solution to treat mitral valve regurgitation, a serious and poorly served condition affecting millions of cardiac patients. Current treatment options are limited since conventional surgical treatments are only appropriate for a small percentage of these patients. Tiara is intended to provide a minimally invasive transcatheter replacement for the mitral valve.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts